MSB-GVHD001
MSB-GVHD001 showed that donor bone marrow stromal cells, given twice a week for a month, helped about seven in ten children whose acute graft-versus-host disease had not settled on steroids, which supported the first US approval of a mesenchymal stromal cell therapy in 2024.
Overview
MSB-GVHD001 was an open-label, single-arm phase 3 study of remestemcel-L, culture-expanded mesenchymal stromal cells from the bone marrow of healthy adult donors, in children with primary steroid-refractory acute graft-versus-host disease after a donor stem-cell transplant who were naive to other immunosuppressant therapies for it. According to the US label, patients had grade B to D disease (excluding grade B skin disease alone), 67 percent had been transplanted for a blood cancer and 33 percent for a non-malignant disease. Remestemcel-L was infused at 2 million cells per kilogram twice a week for four weeks (eight infusions). The primary endpoint was overall response (complete plus partial) at day 28, tested against a prespecified historical control rate of 45 percent.
In the 54 treated children the day-28 overall response was 70.4 percent (P = .0003 against 45 percent) and was sustained through day 100, with complete responses rising from 29.6 percent at day 28 to 44.4 percent at day 100. Overall survival was 74.1 percent at day 100 and 68.5 percent at day 180, and children who had responded by day 28 were more likely to be alive at day 100 (86.8 against 47.1 percent) and day 180 (78.9 against 43.8 percent). No infusion-related toxicities were identified (Biology of Blood and Marrow Transplantation 2020).
The US label reports the same 54 children as an overall response of 70 percent (38 of 54, 95% CI 56.4 to 82.0) with a median response duration of 54 days. The registry counts 55 participants in its full analysis set, one more than received treatment, and records the study as completed in April 2018. The FDA approved remestemcel-L (Ryoncil) in December 2024 for steroid-refractory acute graft-versus-host disease in children aged two months and older. The trial treats a complication of transplant rather than a cancer, so it carries no cancer ids.
- 70.4 out of 100 people had their tumour shrink with Remestemcel-L.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- 74.1 out of 100 people alive with Remestemcel-L.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- 68.5 out of 100 people alive with Remestemcel-L.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- These results apply to the people the trial enrolled: Steroid-refractory acute graft-versus-host disease in children after allogeneic stem-cell transplant, with no second-line therapy for it yet: remestemcel-L alone, single arm, judged against a historical control. People in a different situation may not see the same effect.
- Only 55 people took part, so the numbers are less certain than in a large trial.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
55 enrolled.
Against a prespecified historical control of 45%, P = .0003; complete response 29.6%
SourceSimilar pages
not linked directly; found by shared links- PersonXiaojun Huang
Shares Graft-versus-host disease (GVHD) and graft-versus-leukaemia, Allogeneic stem cell transplant (allo-SCT), Allogeneic (off-the-shelf) cell therapy.
- TrialROCKstar
Shares Graft-versus-host disease (GVHD) and graft-versus-leukaemia, Allogeneic stem cell transplant (allo-SCT).
- Key paperBelumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study
Shares Graft-versus-host disease (GVHD) and graft-versus-leukaemia, Allogeneic stem cell transplant (allo-SCT).
- TermConditioning regimen (myeloablative, reduced-intensity)
Shares Graft-versus-host disease (GVHD) and graft-versus-leukaemia, Allogeneic stem cell transplant (allo-SCT).
- CancerPost-transplant lymphoproliferative disorder (PTLD)
Shares Graft-versus-host disease (GVHD) and graft-versus-leukaemia, Allogeneic stem cell transplant (allo-SCT), Allogeneic (off-the-shelf) cell therapy.